A real-world pharmacovigilance study of FDA adverse event reporting system events for Capmatinib
Abstract Capmatinib is a potent selective mesenchymal-epithelial transition inhibitor approved in 2020 for the treatment of metastatic non-small cell lung cancer. As real-world evidence is very limited, this study evaluated capmatinib-induced adverse events through data mining of the FDA Adverse Eve...
Bewaard in:
| Hoofdauteurs: | , , , , , , , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Nature Portfolio
2024-05-01
|
| Reeks: | Scientific Reports |
| Online toegang: | https://doi.org/10.1038/s41598-024-62356-w |
| Tags: |
Geen labels, Wees de eerste die dit record labelt!
|